Michael O’Donnell

Michael O’Donnell is a board-certified urologist specializing in bladder cancer. His basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy, particularly the anti-cancer mechanisms of BCG. Dr. O’Donnell has pioneered several new sequential combination therapies involving adriamycin, gemcitabine, docetaxel and mitomycin for treating BCG-resistant/recurrent bladder cancers. His research efforts also include exploration of methods to detect bladder cancer at earlier stages. He is currently lead investigator on two national clinical trials, including a >1000 patient trial evaluating BCG in combination with interferon, holds several US patents, and serves on the editorial board of the Journal of Urology. Dr. O’Donnell is Professor of Urology at the University of Iowa.